Is a family history of venous thromboembolism a contraindication to combined hormonal contraception?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Family History of Blood Clot and Combined Contraceptives

A family history of venous thromboembolism in a first-degree relative before age 60 years is a relative contraindication to combined hormonal contraception, not an absolute contraindication—but progestin-only methods should be the first-line choice for these women. 1

Clinical Approach

Risk Stratification by Family History

The key determinant is age of the affected first-degree relative when the VTE occurred:

  • Before age 60 years: Combined estrogen-progestin contraception is a relative contraindication 1
  • Before age 50 years: Some guidelines use this more conservative threshold 1
  • Before age 45 years: UK guidelines use this cutoff 2

Evidence on Risk Magnitude

Family history substantially increases VTE risk when combined with hormonal contraception:

  • Family history alone confers an OR of 2.38 for VTE 3
  • Combined oral contraceptive use alone confers an OR of 2.53 3
  • The combination yields an OR of 6.02 (5.02-7.22) for VTE 3
  • Importantly, there is no significant interaction between these risk factors—the risks multiply rather than synergize 3

Recommended Contraceptive Strategy

First-line options for women with positive family history:

  • Microdose or macrodose progestin-only pills (desogestrel, norethisterone, levonorgestrel) 1
  • Levonorgestrel intrauterine device (IUD) - no increased VTE risk (RR 0.61,95% CI 0.24-1.53) 4
  • Copper IUD - highly effective with no thrombotic risk 4, 5
  • Subdermal progestin implant (etonogestrel) - appears safe but limited data 4, 6

Avoid:

  • All combined hormonal contraceptives (pills, patches, vaginal rings) 1
  • Depot medroxyprogesterone acetate (DMPA) - may increase VTE risk (OR 2.19-2.67) 1, 4, 6

When Thrombophilia Testing is Indicated

Screening should be limited to women with first-degree family history of VTE before age 60 1. If testing is pursued, include:

  • Prothrombin time (PT)
  • Activated partial thromboplastin time (aPTT)
  • Antithrombin levels
  • Protein C and S levels
  • Factor V Leiden mutation
  • Prothrombin (FII) 20210A mutation 1

Routine screening before prescribing contraception is NOT recommended in women without family history 1, 5.

Important Clinical Caveats

What Does NOT Contraindicate Hormonal Contraception

  • Superficial venous thrombosis (personal history) does not contraindicate hormonal contraception 1
  • Family history in relatives beyond first-degree
  • Family history of VTE occurring after age 60 years

Real-World Prescribing Patterns

Studies show that 18.9-25.9% of combined hormonal contraceptive prescriptions may be inappropriate when considering family history 2. Compliance with guidelines considering family history could prevent 13.5-18.5% of VTEs in CHC users 2. This suggests that family history is often overlooked or underweighted in clinical practice.

The Relative vs. Absolute Distinction Matters

The designation as a "relative" rather than "absolute" contraindication means that in exceptional circumstances—after thorough counseling about the 6-fold increased risk and consideration of all alternatives—combined hormonal contraception could theoretically be used 1. However, the clinical reality is that safer, equally effective alternatives exist, making this choice difficult to justify in routine practice.

Age Considerations

The thrombotic risk of combined hormonal contraceptives increases significantly with age, particularly beyond 40 years 1, 7. Women with family history who are also older face compounded risk and should be strongly steered toward progestin-only or non-hormonal methods.

Related Questions

What estrogen‑free contraceptive options are appropriate for a 19‑year‑old woman with a new left‑leg deep vein thrombosis who is taking apixaban (Eliquis)?
What birth control options are appropriate for a healthy 19‑year‑old woman who is not pregnant, does not smoke heavily, and has no history of thromboembolic disease, hypertension, migraine with aura, liver disease, or estrogen‑sensitive cancer?
Should a patient with a provoked deep vein thrombosis who is taking combined oral contraceptive pills stop the estrogen‑containing contraception while on anticoagulation?
Can a 48-year-old perimenopausal female with obesity (Body Mass Index (BMI) of 37) use Nextstellis (Drospirenone and Estetrol) Oral Contraceptive Pill (OCP) for contraception?
In a woman with polycystic ovary syndrome who has a first-degree relative with venous thromboembolism before age 60, what contraceptive regimen is recommended?
Do patients who undergo total thyroidectomy for papillary thyroid cancer require calcium supplementation?
How do we know that the early worsening of diabetic retinopathy observed with GLP‑1 receptor agonist therapy is transient?
What components are measured in a standard lipid panel (lipid profile)?
Is the standard lipid panel (total cholesterol, LDL‑cholesterol, HDL‑cholesterol, triglycerides, and calculated non‑HDL‑cholesterol) limited to the United States?
In a woman with polycystic ovary syndrome who has a first-degree relative with venous thromboembolism before age 60, what contraceptive regimen is recommended?
What ANA titer (dilution ratio) is considered positive for systemic lupus erythematosus and indicative of active disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.